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Key Points: 
 
• The circadian rhythm of the hypothalamic-pituitary-adrenal (HPA) axis is 
composed of 45-60 minute pulses of cortisol, known as an ultradian 
rhythm. 
 
• The corresponding pulsatility in cortisol-receptor binding is important for 
normal functioning with varying effects on gene transcription. 
 
• Cortisol binding globulin (CBG) acts as a reservoir and effectively delivers 
free cortisol to inflammatory sites. 
 
• The value of point assessments of HPA axis function in the Intensive Care 
Unit is is therefore probably of minimal use other than to diagnose absolute 
deficiency.  
 
 
 
  
 
The basic constituents of the hypothalamic-pituitary-adrenal (HPA) axis will be 
familiar to most physicians because the “stress response” is seen following any 
significant illness, injury or surgery. However, this article seeks to highlight the 
substantial advances in understanding that have been made in the last decade and 
how these may alter treatment and guide future research. 
 
The Hypothalamic-Pituitary-Adrenal Pathway 
A simple schematic of the HPA axis can be seen in Fig 11. The paraventricular 
nucleus (PVN) of the hypothalamus is the ‘control centre’ of the HPA axis. It 
receives input from multiple other centres: 
 
Suprachiasmatic nucleus (SCN):  The body’s “biological clock” provides diurnal 
information, modulating inhibitory gain to the PVN, resulting in low activation 
during periods of sleep, increasing in anticipation of awakening and peaking in the 
morning, the basis of the circadian rhythm. 
Brainstem nuclei: Delivers information from physiological changes such as 
hypotension or inflammation. 
Limbic region: Provides stimulation from cognitive or emotional stressors. 
 
Sympathetic/Sensory:  In addition to higher centre inputs at the hypothalamus, 
there is also extensive sensory and sympathetic innervation to the end target, the 
adrenal glands, via the splanchnic nerves. Both cholinergic pre-ganglionic and 
catecholaminergic postganglionic sympathetic fibres synapse at the adrenal gland 
and appear to sensitise it to adrenocorticotrophic hormone (ACTH), increasing 
cortisol release. This is probably an indirect effect - vasodilation leads to a higher 
adrenal blood flow which in turn means more cortisol output. Furthermore, the 
adrenal gland has autonomous clock genes exerting additional circadian control 
on steroidogenesis and ACTH sensitivity. This effect may be modulated directly by 
light as well as possibly via splanchnic innervation. 
 
The PVN contains two types of neuroendocrine cells: 
  
Magnocellular neurons synthesise arginine vasopressin (AVP - also known as anti-
diuretic hormone, ADH), which is then transported to the posterior pituitary (an 
embryological down-growth from the hypothalamus), for storage and subsequent 
release. 
 
Parvocellular neurons synthesise corticotrophin-releasing hormone (CRH), which 
is secreted from the median eminence of the hypothalamus into the hypophyseal 
portal circulation. CRH acts upon corticotrophs in the anterior pituitary 
prompting secretion of ACTH into the systemic circulation, which in turn 
stimulates cortisol release from the zona fasciculata of the adrenal cortex. Cortisol 
is synthesized de novo, secreted and circulating free cortisol then exerts a negative 
feedback effect at the pituitary to reduce ACTH secretion and inhibit CRH release 
at the PVN. “Normal’ people under unstressed conditions normally produce the 
equivalent of about 20 – 25mg hydrocortisone per day. 
 
Fig 1 Near Here 
 
Ultradian Rhythm of ACTH & Cortisol 
The familiar circadian rhythm of cortisol and ACTH (high in the early morning and 
low in the late afternoon and evening) is in fact composed of an ultradian rhythm 
of pulses lasting around 45 – 60 minutes2. The peaks of the circadian rhythm are 
generated by high amplitude pulses and the troughs by smaller pulses, or non-
pulsatile activity (see Fig 2). The term ultradian refers to any biological cycle that 
repeats more frequently than daily, whereas circadian rhythms follow a one-day 
cycle. This pulsatility used to be considered to come from a pulse generator within 
the hypothalamus, but recent studies have concluded that it is more likely 
generated from the positive feed-forward from the pituitary (ACTH) and negative 
feed-back relationship from the adrenal (cortisol)3. The driver ‘pushing’ the 
system is the hypothalamic CRH. It may be imagined on a simple level like a 
“Newton’s Cradle” system; where ACTH and cortisol are two balls oscillating at 
alternate ends and CRH is the driving force to maintain and vary propulsion.  
 
Fig 2 Near Here 
  
 
Ultradian rhythms are relative commonplace in neurological and other 
neuroendocrine pathways responsible for maintaining homeostasis. Pulsatile 
signalling affords many benefits including greater signal control, higher energy 
efficiency and enables receptor recovery between pulses, which is essential for 
maintaining target responsiveness. Since pulses can vary in amplitude, duration, 
shape and frequency, pulsatile signalling also transmits much greater information 
to the target receptor when compared with continuous signalling. This can be 
illustrated by comparing a colour television image (where each pixel can vary in 
frequency and amplitude) to that of a black and white television (where pixels 
may only vary in amplitude). Since the ultradian pattern of ACTH and cortisol 
release is relatively newly determined, much of the research seeking to accurately 
quantify HPA activity in health and following injury or surgery may be inaccurate 
due to insufficient sampling frequency. 
 
Pulsatility is important – patients with absolute cortisol deficiency (Addison’s 
disease), who take physiological cortisol replacement but lack the pulses, are 
twice as likely to die as their peers4. Pulses of cortisol also exhibit characteristics 
of an effective refractory period - the same stressor applied at different phases of 
the ultradian cycle appears to elicit differing magnitudes of cortisol response. An 
exaggerated response occurs if the stressor is applied during the rising cortisol 
phase, whereas a much smaller or no response is generated when the same 
stimulus is applied during the falling phase of the cycle. Whether this also applies 
to humans during sepsis or following surgery remains as yet unstudied. 
 
Cortisol Synthesis, Metabolism and Regeneration 
Like the other endogenous steroid hormones, cortisol is synthesised from 
cholesterol. Since cortisol is lipophilic and will readily pass through membranes, 
it cannot be packaged in vesicles, but instead must be rapidly manufactured de 
novo. Cortisol steroidogenesis begins with the binding of ACTH to the membrane 
bound G-protein coupled receptor (the melanocortin 2 receptor - MC2-R) on the 
surface of zona fasciculata cells. This triggers the cAMP - protein kinase A cascade 
which in turn activates steroidogenic acute regulatory protein (StAR) in the 
  
mitochondria. StAR protein is important since it orchestrates the transportation 
of cholesterol from the outer to the inner mitochondrial membrane and is the rate-
limiting step in steroidogenesis. Once inside the mitochondrion, cholesterol is 
converted into the steroid precursor, pregnenolone by Side Chain Cleavage 
enzyme (CYP450SCC). Cortisol is then constructed via a series of enzyme catalysed 
steps within the mitochondrion and endoplasmic reticulum, before being released 
into the circulation. 
 
Cortisol clearance occurs principally by hepatic metabolism via 5α- and 5β- 
reductases and is eliminated by the kidneys via 11β-hydroxysteroid 
dehydrogenase (11β-HSD) type 2. This is balanced by regeneration of cortisol 
from cortisone in the liver and adipose tissue by 11β-HSD type 1. 
 
Cortisol Binding Globulin (CBG) 
As a steroid hormone, cortisol is fat soluble and thus relatively insoluble in plasma. 
As a result, it is highly protein bound; 80-90% to cortisol binding globulin (CBG), 
10-15% to albumin, with only 5% remaining unbound and free to cross cell 
membranes and bind to receptors. 
 
Cortisol binding globulin is a 50-60kDa protein, part of the serpin (serine 
proteinase inhibitor) family and is synthesised mainly in the liver. CBG is also 
found in small amounts in lung, kidney and testes tissue where it may have a role 
in regulating local cortisol levels within each organ. CBG is important because as 
a transporter and reservoir of cortisol in the blood, it plays a significant role in the 
fraction of free cortisol available to pass into cells. Each CBG molecule binds to one 
cortisol molecule and thus binding is saturable with a finite binding capacity. This 
characteristic of the system means it is extremely efficient, since any large pulse 
of cortisol exceeding the CBG binding capacity or physiological fall in the CBG level, 
will result in a significant increase in the free fraction of cortisol in the blood, 
amplifying the signal to the tissues. Serum CBG levels have a diurnal fluctuation, 
falling slightly in the day and increasing at night and thus accentuating the overall 
circadian rhythm of cortisol. 
 
  
Cortisol is preferentially delivered to sites of inflammation by CBG. CBG behaves 
as a “thermocouple”, showing marked decline in affinity for cortisol at higher 
temperatures, such as during fever5. Cortisol is also liberated from CBG by 
activated neutrophils which release elastase, an enzyme that cleaves and 
irreversibly destroys CBG. Local inflammatory changes in pH do not affect CBG 
affinity, but do reduce the affinity of albumin to cortisol and therefore further 
enhance the effect. 
 
Glucocorticoid Receptors 
Since glucocorticoids are lipophilic, they readily cross the phospholipid bilayer of 
cell membranes and bind to intracellular glucocorticoid receptors (GR). Stabiliser 
proteins aid the GR-ligand complex formation and cause dimerisation of two GR-
ligand complexes. The dimerised GR-ligand complexes can then be transported 
into the cell nucleus, where they transiently bind to deoxyribonucleic acid (DNA), 
acting as effective transcription factors. The Glucocorticoid – Receptor complex 
oscillates on and off the DNA, with each interaction lasting 10-20 seconds. It is this 
rapid oscillation that allows HPA output to respond quickly to stressors. Although 
GR follows a ‘saturable’ pharmacokinetic pattern, we do not know at what 
concentration of cortisol the receptors are saturated in different tissues. The 
interaction of the ultradian rhythm with receptor binding is important for 
physiological functioning. Transcription of glucocorticoid responsive genes 
occurs in pulses that tracks the pulses of cortisol – i.e. pulsatile receptor binding 
leads to pulsatile gene expression6. The genetic output of glucocorticoids can be 
both positive (cause transcription) and negative (repress transcription) and be 
transient or continuous. The characteristics of this output is exquisitely sensitive 
to patterns, with pulsatile glucocorticoid exposure exerting a greater control over 
certain target genes and a smaller effect on others in comparison to constant 
presentation as is seen in glucocorticoid based therapeutics.    
 
Some effects of glucocorticoids are too fast to be the result of transcription, with 
effects seen in seconds or minutes (transcription takes 20 – 40 minutes). Thus 
some glucocorticoid receptors are membrane bound and act via ion channels and 
secondary messenger systems. These can cause T-cell inhibition in the immune 
  
system and activation of endothelial nitric oxide synthase (eNOS) in 
neurovascular tissue. 
 
HPA Axis function following Major Surgery or Critical Illness 
Significant stressors, such as major surgery or critical injury or illness, pose 
significant challenges to the body’s homeostasis. They trigger compensatory 
autonomic and neuro-endocrine mechanisms, some of which are fairly primitive 
in evolutionary terms. The HPA axis is pivotal to the body’s homeostatic response 
and has evolved to react rapidly, with an amplification of effect: Increased cortisol 
production, reduced circulating CBG and albumin levels, with a reduced affinity 
for cortisol, all leads to a net increase in both total and free serum cortisol. Cortisol 
clearance also seems to be reduced during major stress, such as severe sepsis7.  
This is possibly as a result of the accumulation of circulating bile salts inhibiting 
the enzymes that breakdown cortisol or a reduction in liver and kidney perfusion. 
CBG cleavage by neutrophil activity ensures cortisol is optimally targeted at areas 
of inflammation. 
 
In addition to stimulation of the higher inputs to the hypothalamus, production of 
pro-inflammatory cytokines; tumour necrosis factor α (TNF-α) and interleukins -
1 and -6 (IL-1 and IL-6) cause direct stimulation of CRH and ACTH. Over the first 
24 hours, ultradian pulses in ACTH and cortisol are seen to be significantly 
magnified8 (See Fig 3). However, by the first postoperative day, ACTH levels 
typically return to normal, whereas cortisol pulses remain elevated. This suggests 
that the mechanisms controlling the adrenal output may be different or sensitised 
differently in acute systemic inflammation. 
 
Fig 3 Near Here 
 
The inflammatory cytokines TNF-α, IL-1 and IL-6 have varied effects on the 
adrenal gland. There is a high density of IL-6 receptors in the zona fasciculata of 
the adrenal gland and the corticotroph cells of the pituitary.  They increase cortisol 
production in cell culture, in animal models and in humans. IL-1 also increases 
cortisol synthesis, but to a lesser extent. TNF-α has different effects on cortisol 
  
synthesis depending on the concentration; at low concentrations inhibitory effects 
appear to dominate and at higher concentrations stimulatory effects predominate. 
 
 
Modulation of the HPA axis response to Surgery 
HPA axis activation and elevated cortisol levels should be regarded as a response 
to the inflammation rather than a driver. Therefore, in broad terms, the greater 
the tissue damage, the greater the levels of activation of the HPA axis and the 
higher the cortisol level. However, this is a rather one-dimensional way of looking 
at the HPA axis after surgery – the timing of the rise and patterns are also 
important. For example, laparoscopic cholecystectomies have an earlier rise in 
cortisol than open cholecystectomy, although overall levels are higher and persist 
longer in the open cholecystectomies.  
 
Multiple strategies have been tried to modulate HPA axis activity around the time 
of surgery, although it is difficult to see what benefit reducing cortisol production 
in response to the same operation brings. An appropriate amount of corticosteroid 
is required to protect the body from uncontrolled inflammation at one end of the 
spectrum and circulatory failure at the other – high-dose corticosteroids are 
associated with a poor outcome, as is too little. It must be remembered that the 
high-dose exogenous steroids associated with poor outcomes 
(methylprednisolone in sepsis9 and head injury10) have potencies many times 
more than is physiologically possible. 
 
Effective neuraxial anaesthesia can block the somatic and autonomic innervation 
to both the hypothalamus and directly at the adrenals, and so could potentially 
reduce HPA activation. Systemic analgesics can directly and indirectly affect the 
HPA axis - for example, opioids suppress the hypothalamic-pituitary-gonadal-
adrenal pathway. Chronic opioid use is well recognised to cause hypogonadism 
and occasionally adrenal suppression. Use of non-steroidal-anti-inflammatory 
drugs prior to surgery can reduce levels of inflammatory mediators, but has no 
direct effect on the HPA axis. Reducing the inflammatory response to surgery is 
  
best achieved by adjusting surgical technique to minimise tissue damage, for 
example by using minimally invasive surgery. 
 
HPA Axis Dysfunction and Critical Illness 
The link between adrenal dysfunction and circulatory failure has been recognized 
for over a century. In patients with septic shock who are resistant to standard 
treatment (antibiotics, fluids, vasopressors and inotropes), a syndrome of relative 
adrenal insufficiency has been postulated – Critical Illness Related Corticosteroid 
Insufficiency (CIRCI). This has also been postulated to exist in many other 
syndromes of systemic inflammation, such as burns. However, crystallisation of 
this phenomenon has proved elusive, with measurements of serum, urine and 
salivary cortisol, ACTH responsiveness and eosinophil count all seeming of little 
value. This was reflected in the consensus guidelines produced by the American 
College of Critical Care Medicine in 200811. Given that cortisol (and ACTH) may 
vary by up to 600nmol/l during the ultradian pulse, any test involving infrequent 
cortisol measurement or ACTH responsiveness is unlikely to be useful in this set 
of patients. Whether in fact this group of patients does really exist and how to 
diagnose and treat them is yet to be established. 
 
Therapeutic use of Corticosteroids during Critical Illness 
The use of exogenous corticosteroids during critical illness and their benefits is a 
different and equally contested debate. Use of high dose corticosteroids (>400mg 
hydrocortisone or equivalent per day) at immunosuppressive doses in sepsis has 
been discarded since the mid 1990’s when multiple studies and two meta-
analyses revealed no outcome improvement and a potential increase in the 
incidence of superinfection. Over the last two decades, attention has focused on 
lower doses of corticosteroids (<400mg hydrocortisone or equivalent per day). 
The first major randomised controlled trial was published by Annane et al. in 
200212. It concluded that there was no overall mortality benefit with the use of 
corticosteroids in sepsis, although perhaps there was a benefit in those failing an 
ACTH stimulation test. CORTICUS, the largest randomised control trial to date, 
recruited 600 patients and showed no mortality benefit with corticosteroid use 
even in that cohort of patients considered to have ‘adrenal insufficiency’13. Use of 
  
random cortisol levels or the ACTH stimulation test as a marker of adrenal 
insufficiency in sepsis has subsequently been discredited and is no longer 
advocated. The latest and largest RCT to compare hydrocortisone with placebo in 
septic shock, called ADRENAL (www.clinicaltrials.gov NCT01448109), aims to 
recruit 3800 patients and started in 2012, with a proposed completion date of late 
2016.  
 
Large scale reviews and meta-analyses have regularly been undertaken to assess 
the role of steroids in sepsis of which the latest, the Cochrane review was 
published in December 201514. All have included a disparate collection of smaller 
studies, which have used different synthetic corticosteroids, at a variety of doses 
and treatment durations, by bolus and continuous infusion - all factors which may 
result in very different physiological and transcriptional effects and outcome. 
Overall, the use of low-dose corticosteroids in sepsis may only have a small 
positive impact on all-cause mortality, but they do consistently appear to reverse 
shock more rapidly, reduce the number of ventilation days and length of stay on 
the ICU.  
 
Corticosteroid Therapy in Cardiac Surgery 
Cardiac surgery evokes a significant acute inflammatory response both from use 
of cardiopulmonary bypass and tissue destruction from the surgery itself. There 
is a theoretical benefit of supplemental corticosteroids to obviate some of the 
inflammatory response. However, since survival rates following cardiac surgery 
are greater than 98%, extremely large trials are required to be of adequate power 
to demonstrate statistically significant changes in mortality. The vast majority of 
studies have looked at large, immunosuppressive doses of methylprednisolone 
and dexamethasone rather than the low-dose hydrocortisone predominant in 
sepsis. The two largest placebo controlled randomized trials have only recently 
been published; the DECS trial15 in 2012, using a single dose of dexamethasone 
(n=4,494 patients) and the SIRS trial16 in 2015, using methylprednisolone 
(n=7,507 patients). Neither study has revealed any significant difference in 
mortality or major morbidity and thus the routine use of corticosteroids in adult 
cardiac surgery is currently not justified. 
  
 
Patients on Long-term Corticosteroids and Surgery 
There is no evidence that anything other than absolute corticosteroid deficiency is 
associated with circulatory failure after surgery. Traditionally, surgical patients 
likely to have a suppressed HPA axis from long-term steroid therapy would 
receive an increased dose of steroid during the perioperative period - the theory 
being to replicate the endogenous stress response following surgery. However, 
converting patients’ regular steroids to an IV equivalent (see table 1) whilst they 
are not eating and drinking is probably all that is required, although many 
guidelines do not yet reflect this. The caveat to this are patients with Addison’s 
disease, who are unable to produce ANY endogenous cortisol and thus do require 
larger steroid doses during the surgical period17. 
 
Conclusion 
The HPA axis is a dynamic system that has evolved to rapidly respond to stressors. 
Cortisol secretion is pulsatile and this pulsatility has a real impact on physiological 
functioning in both health and disease. Normal function and control of the HPA 
axis after major surgery and critical illness is still not yet fully understood – nor is 
its place as an avenue of therapy for these conditions. Too much corticosteroid is 
associated with an excess mortality and morbidity, too little is associated with 
circulatory failure and death. Where the transition points are, we are still to find 
out. 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1 
Dose equivalency of corticosteroids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corticosteroid Equivalent Dose 
Hydrocortisone 40mg 
Prednisolone 10mg 
Triamcinolone 8mg 
Methylprednisolone 8mg 
Dexamethasone 1.5mg 
Betamethasone 1.2mg 
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Figure Legends 
 
Fig 1. Basic hypothalamic-pituitary-adrenal axis control. Arrows indicate positive 
feed-forward. Blocks indicate negative feedback. CNS – Central nervous system. 
SCN – supra-chiasmatic nucleus. PVN – paraventricular nucleus.  CRH – 
Corticotrophic releasing hormone. ACTH – Adrenocorticotrophic hormone.  
(Reproduced with permission from reference 1) 
 
Fig 2. 24 hour ACTH and cortisol profile of a healthy volunteer. The ultradian 
rhythm is seen underlying the diurnal rhythm. Diurnal highs are generated by 
large amplitude pulses and lows by smaller, or minimal activity. ACTH is seen to 
precede cortisol. 
 
Fig 3.  Stylised ultradian rhythms of cortisol in Healthy subjects and in those 
having cardiac surgery. 
 
 
Table Legends 
 
Table 1. Dose equivalency of corticosteroids 
 
  
  
MCQ’s : Hypothalamic-pituitary-adrenal (HPA) function during major 
surgery and critical illness 
 
Question 
1. Regarding the hypothalamic-pituitary-adrenal axis and the ultradian 
rhythm 
(a) The suprachiasmatic nucleus (SCN) has an inhibitory effect on the 
paraventicular nucleus (PVN) and forms the basis of the circadian 
rhythm.  
(b) Neurons in the paraventricular nucleus of the hypothalamus 
synthesise, oxytocin, arginine vasopressin and corticotrophin 
releasing hormone. 
(c) The ultradian rhythm consists of hourly cortisol pulses which begin 
in the early morning and peak mid-morning. 
(d) Loss of cortisol pulsatility is thought to be a factor in the increased 
mortality seen in patients with Addison’s disease. 
(e) The pulsatility of cortisol causes pulsatile gene expression within 
cells with varying transcriptional effects, but this system is inherently 
energy inefficient. 
 
Answers 
1. (a) True The suprachiasmatic nucleus is the brain’s “biological clock” 
providing diurnal information to the paraventricular nucleus 
and inhibiting hormone release. 
(b) True Oxytocin and arginine vasopressin are synthesised by 
magnocellular neurons in the paraventricular nucleus (PVN) 
and stored in the posterior pituitary. Corticotrophin releasing 
hormone (CRH) is synthesised by parvocellular neurons in the 
PVN and released from the median eminence of the 
hypothalamus. 
(c) True In health, pulses of ACTH and cortisol last 45-60 minutes and 
begin at about 2am or 3am in preparation for awakening. 
Pulses diminish after lunchtime. See fig. 2. 
(d) True The age related mortality for patients with Addison’s disease 
is between two or three times higher than seen in the general 
population. 
(e) False Pulsatile signalling is believed to be highly energy efficient 
since it enables greater signal control, intricately varying gene 
transcription as well as allowing receptor recovery and 
optimising responsiveness.   
 
  
  
Question 
2. Cortisol 
(a) Is stored in vesicles within the zona fasciculata of the adrenal cortex. 
(b) Cortisol steroidogenesis is stimulated by binding of corticotrophin 
releasing hormone (CRH) to the membrane bound melanocortin 2 
receptor (MC2-R) on the surface of zona fasciculata cells.  
(c) The rate determining step in the production of cortisol is the 
transportation of cholesterol through the mitochondrial membrane 
by steroidogenic acute regulatory protein (StAR). 
(d) Glucocorticoid receptors may be intracellular or membrane bound. 
(e) Is metabolised predominantly by plasma 11β-hydroxylases. 
 
Answers 
2. (a) False Cortisol is lipophilic and so not amenable to storage in 
vesicles, instead it is synthesised de novo. 
(b) False Cortisol steroidogenesis is stimulated by binding of 
adrenocorticotrophic hormone (ACTH) not corticotrophin 
releasing hormone (CRH). 
(c) True  
(d) True Glucocorticoid receptors (GR) may be intracellular, the GR-
ligand complexes dimerising before binding to DNA within the 
cell nucleus and affecting gene transcription. 
Some GR’s are membrane bound, G-protein coupled receptors 
or ion-gated ion channels and this binding accounts for the 
more rapid effects of corticosteroids. 
(e) False Cortisol is hepatically metabolised by 5α- and 5β- reductases 
before being renally excreted. Cortisol is regenerated from 
cortisone by 11β-hydroxysteroidal dehydrogenase type 1 in 
the liver and fat cells. 
 
  
  
Question 
3. Cortisol binding globulin (CBG) 
(a) Is synthesised predominantly in the liver. 
(b) As a serpin (serine proteinase inhibitor), it is a larger protein than 
albumin with a molecular weight of 150-160kDa. 
(c) Has a finite binding capacity which is typically exceeded during times 
of severe physiological stress. 
(d) More than 75% of serum cortisol is bound to CBG. 
(e) CBG affinity for cortisol alters with pH and temperature. 
 
Answers 
3. (a) True Globulins are made in the liver, immunoglobulins by the 
immune system. 
(b) False Cortisol binding globulin has a molecular weight of 50-60kDa, 
Albumin is 60-70kDa. However, generally globulins have a 
larger molecular weight than albumins. 
(c) True Acting as a carrier and reservoir for cortisol in normal health 
and optimising delivery of free cortisol to target tissues in 
times of physiological stress. 
(d) True Typically 80-90% of cortisol is bound to cortisol binding 
globulin (CBG), 10-15% to albumin. 
(e) False CBG affinity for cortisol reduces with increasing body 
temperature, behaving as a “thermocouple”, however it is 
unaffected by pH. The affinity of albumin to cortisol is reduced 
by reducing pH. 
 
  
  
Question 
4. Commencing a patient on intravenous hydrocortisone would be an 
appropriate treatment 
(a) At a dose of 50mg four times daily until eating and drinking, in a 57 
year old female presenting for laparoscopic cholecystectomy with 
rheumatoid arthritis, usually taking prednisolone 20mg daily. 
(b) Urgently in a hypotensive 35 year old patient with Addison’s disease 
presenting with acute severe abdominal and lower back pain, 
syncope, confusion, agitation and seizures and fever, with 
biochemistry results revealing hyponatraemia, hyperkalaemia and 
hypercalcaemia. 
(c) For 3 to 5 days duration in a 70 year old male following routine aortic 
valve replacement surgery, to reduce the system inflammatory 
response to surgery and cardiopulmonary bypass. 
(d) As an infusion at a rate of 20mg/hr in a 51 year old man with severe 
sepsis secondary to pneumonia, who is ventilated, with multiorgan 
dysfunction requiring noradrenaline, dobutamine and vasopressin 
infusions. 
(e) 100mg at induction and then four times daily until eating and 
drinking normally, in a 42 year old lady with Addison’s disease 
having a total knee replacement, who usually takes 20mg oral 
hydrocortisone twice daily and 100 micrograms oral fludrocortisone 
daily. 
 
Answers 
4. (a) False In this patient presenting for elective intermediate surgery, 
increasing the steroid dose to replicate the endogenous stress 
response is not necessary. One should plan to continue the 
patient’s regular oral prednisolone regime. If they are unable 
to eat and drink, one might consider conversion to an 
intravenous equivalent. Prednisolone 5mg is equivalent to IV 
hydrocortisone 20mg. 
(b) True The symptoms and signs described are characteristic of acute 
adrenal crisis (Addisonian crisis). A life-threatening condition 
resulting from sudden cortisol insufficiency. 
Management includes HDU/ICU care, ventilatory support if 
necessary, IV fluids, vasopressors and inotropes, correction of 
electrolyte disturbances and hypoglycaemia, baseline cortisol 
+ ACTH levels and treatment with hydrocortisone 100mg IV 
stat followed by 100mg four times a day and treating the 
precipitating cause. 
(c) False Two recent placebo controlled randomised trials have shown 
  
no major morbidity or mortality benefit associated with the 
use of corticosteroids following cardiac surgery. Thus routine 
use of hydrocortisone in this setting is not appropriate. 
(d) False Commencement of hydrocortisone either via infusion or 
divided bolus doses might be considered appropriate 
treatment in a patient in septic shock resistant to treatment 
with vasopressors and inotropes. However, a rate of 20mg/hr 
(480mg/day) would be considered high-dose which is 
associated with an increased incidence of superinfection and 
no improvement in outcome. 
(e) True Patients with Addison’s disease, primary adrenal 
insufficiency, are unable to mount a stress response following 
surgery. They therefore require an increase in dose and 
frequency of their hydrocortisone regime. 
For further information consult the Addison’s Disease Self 
Help Group (ADSHG) surgical guidelines, as recommended by 
NICE. 
 
 
 
 
